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Abstract 
Background: Breastfeeding of term infants has been associated with decreased blood pressure 
(BP) in later ages compared to formula feeding. The protective effect of human milk against 
childhood BP has been linked to its docosahexaenoic acid (DHA) content. It is unclear whether 
early exposure to DHA supplementation can benefit offspring from high BP in childhood.   
Objective: to determine whether the amount of DHA fed to infants during infancy influences 
their blood pressure at ages 4, 4.5, 5, 5.5 and 6 years. 
Methods: BP was measured longitudinally from 4 to 6 years of age at 6-months interval, in a 
cohort of 77 children who were randomized at birth into four infant formula groups comprise of 
0.0%, 0.32%, 0.64%, and 0.96% of total fatty acids (FA) from DHA. Both the control and 
intervention groups were subsequently dichotomized into 2 groups based on their weight status 
(≤ 85th and > 85th percentiles), using the Center for Disease Control BMI-for-age growth charts 
(≥ 2 years) reference. A three-way ANOVA model was run to examine the degree of interaction 
among BMI-for-age percentiles, formula group (control vs DHA) and age (4, 4.5, 5, 5.5, and 6 
years) on systolic or diastolic BP.  
Results: Higher BMI-for-age percentiles predicted higher systolic blood pressure (SBP) 
(p=0.0054) but group and age were unrelated to SBP. No variable was related to diastolic blood 
pressure (DBP) in young children. 
Conclusion: Intake of a LCPUFA-supplemented infant formula did not protect against higher 
BP levels seen in overweight/obese children compared to intake of a non-supplemented formula.   
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Chapter 1: Introduction 
Docosahexaenoic acid (DHA), an omega-3 long chain polyunsaturated fatty acid (n-3 
LCPUFA) and arachidonic acid (ARA), an omega-6 (n-6) LCPUFA are essential fatty acids 
found in high concentration in neuronal membranes of the brain. DHA is vital for infant 
neurocognitive development. Thus, having an adequate supply of DHA during late pregnancy 
and the first years of life is critical for proper child growth and development (1). There is 
evidence showing that LCPUFA supplementation of infant formula during infancy may lower 
childhood blood pressure (BP) when compared to standard formula, and may have long-term 
benefit by reducing risk of hypertension-related diseases in adulthood (2). In addition, there are 
strong observational and clinical evidence supporting that higher BMI in youth is associated with 
harmful levels of BP and lipids, putting this population at increased risk of CVDs later in life (3). 
In adults, the heart health benefits of consuming a diet rich in omega-3 has been well 
documented. Epidemiological studies on dietary omega-3 consumption of different populations 
have demonstrated that in countries where consumption of fish is high, people tend to have 
higher levels of red blood cell (RBC) DHA, and lower risk of cardiovascular disease (CVD). 
Fish oil contains both DHA and EPA (eicosapentanoic acid), another omega-3 FA, found mainly 
in cold-water fatty fish (e.g., salmon, mackerel, and sardines). The cardiovascular benefits of fish 
oil supplementation have also been supported by numerous randomized controls trials (RCTs). A 
recent meta-analysis of RCTs concluded that supplementation with DHA and EPA, lowers 
systolic blood pressure (SBP), in both hypertensive and normotensive groups compared to the 
placebo group (4) . 
In infants, breastfeeding is the recommended feeding practice (5). Breastfeeding of term 




et al. (8), showed that breastfeeding was inversely associated with overweight/obesity (pooled 
OR: 0.87; 95% CI: 0.76; 0.99) and breastfed infants tended to have lower BP than formula-fed 
infants (8, 9). The lower BP seen in breastfed infants has been associated with LCPUFA and, 
more specifically, with the DHA content of human milk (1). However, DHA levels in breastmilk 
depends partly on maternal diet, and U.S. pregnant and lactating women have very low DHA 
levels compared to other parts of the world (10); this is mainly due to the consumption of a 
“western diet” that lacks adequate amounts of DHA.  In this respect, for infants who are not 
breastfed, early supplementation of the infant diet with LCPUFA may be beneficial in protecting 
children from developing chronic diseases such as hypertension later in adulthood.  
Justification for Further Investigation 
Data on LCPUFA supplementation during infancy and its effect on BP in childhood is 
very limited. Currently, there is only a single multi-center RCT that investigated the effect of 
LCPUFA supplemented infant formula during infancy and childhood BP as a primary outcome. 
This study demonstrated a positive association between DHA supplementation during infancy 
and lower BP at 6 years of age (2). Another RCT looked at the impact of LCPUFA 
supplementation in infancy (only from birth to 2 months of age) on cardiovascular health and 
anthropometric measures, including childhood BP at 9 years of age. They found no difference in 
BP between the LCPUFA supplemented bottle-fed and breast-fed babies (11). Two other studies 
have looked at fish oil supplementation and BP in childhood and had different outcomes. One 
showing positive effect of fish oil supplementation (12), and one showing no effect (13). Overall, 
RCTs on LCPUFA intake and childhood BP have resulted in mixed findings with some showing 




The limited body of literature on DHA supplementation of term babies and BP later in 
childhood needs further investigation because of inconsistent results surrounding this topic. The 
dose of DHA supplementation during infancy, as well as duration of intake, age and method of 
analysis remain very different among studies, making their comparison challenging.  
The present secondary data analysis of this RCT comprised of a sample of healthy term 
infants who were fed one of four different amounts of DHA throughout infancy gave us the 
prospect to address some of the existing gaps found in the literature, including DHA dose and 
duration of intake and its effect on childhood BP, which is a risk factor for CVD. We examined 
the dose-response relationship between DHA-supplemented intake at three different doses 
(0.32%; 0.64%; and 96%) of total fatty acid intake as DHA and 0.64% ARA and also the 
combined groups that were provided DHA and ARA. These were compared to 0% DHA 0% 
ARA, the control formula, for childhood SBP and DBP by BMI-for-age (≤85th and > 85th 
percentiles). This is also the first study to look at a longer period of DHA intake from birth to 12 
months of age.  
Statement of purpose 
The purpose of this project was to determine whether the amount of DHA fed to infants 
during infancy influences their blood pressure at ages 4, 4.5, 5, 5.5 and 6 years.  
Research question 
Does the amount of DHA in formula fed to infants throughout infancy influence their 






Chapter 2: Review of Literature 
Childhood Obesity and High Blood Pressure 
 According to NHANES 2011-2014 data, the prevalence of obesity in US children and 
adolescents, ages 2 to 19 years, remains high at approximately 17% and severe obesity was on 
the rise at 5.8%  (15).  There are strong observational and clinical evidence supporting that 
higher BMI in youth is associated with harmful levels of BP and lipids, putting this population at 
increased risk of CVDs later in life (3). 
Compelling evidence indicates that hypertension in childhood tracks into adulthood (18). 
The prevalence of high BP (HBP), defined as having a SBP/DBP of  >140/ 90 mm Hg, is 
estimated at 29% among U.S. adults (≥ 18 years old) (19) . Hypertension in children and 
adolescents is defined as “the average SBP and /or DBP ≥ 95th percentile for age, gender, and 
height, on 3 or more occasions” (20), and remains one of the leading causes of CVDs (21) . 
Amongst U.S. youths, 1 in 10, aged between 8 and 17 years, has either borderline or HBP (20). 
Uncontrolled HBP can cause damage to the artery wall and lead to the development of 
atherosclerosis (22), which is a risk factor for myocardial infarction.  Other complications 
include risk of stroke, kidney disease, and death, if left untreated (23) . In children, the increased 
rate of obesity and type 2 diabetes is concerning because obesity-associated insulin resistance is 
a risk factor for hypertension and other CVDs (2) . 
Polyunsaturated Fatty Acids 
Dietary FAs are classified based on the number of double bonds and saturation levels. 
Saturated FAs (SFAs) have no double bonds, monounsaturated FAs (MUFAs) have only one 
double bond, and polyunsaturated FAs (PUFAs) have two or more double bonds. The class of 




prevalent dietary PUFAs are from the omega-6 and omega-3 families (24). The essential PUFAs, 
linoleic acid (LA) (18:2n6) and α-linolenic acid (ALA) (18:3n-3), cannot be synthesized by 
humans and need to be taken exogenously. Once consumed, these PUFAs can form long chain 
(LC) PUFAs, omega-3 (n-3) and omega-6 (n-6) FAs (24). 
Through elongations and saturations, PUFAs are transformed to LCPUFAs. ALA forms 
EPA and DHA, and LA is transformed to arachidonic acid (ARA) (1) . A sizeable proportion of 
LCPUFAs found in the brain and the retina are DHA and ARA. DHA and ARA have been 
extensively researched for their role in neural development of the fetus and offspring (1). 
Breastmilk contains DHA and ARA but the amount of DHA in human milk depends on genetics 
(25), maternal diet (largely DHA intake), smoking, socio-economic status and gestational age 
(26).  
LCPUFAs dietary sources 
The best sources of the n-3 LCPUFA, EPA and DHA are marine sources namely fatty 
fish, seafood, and fish oil (27). Other non-marine sources of omega-3 FAs are vegetable oils such 
as walnut oil, linseed oil, flaxseed oil, and canola oil but the conversion rate of ALA from 
vegetable sources to EPA and DHA is estimated to be low at 0.2% and 0.05%, respectively (24). 
Therefore, marine sources and fish oil supplements are considered superior sources of n-3 
LCPUFAs (27) . 
LCPUFAs in infant diet   
The FA composition of human milk is a mixture of saturated fatty acids (SFAs), 
monounsaturated fatty acids (MUFAs) and PUFAs. The main SFA is palmitic acid (C16:0), and 
the major MUFA is oleic acid (18:1). PUFA is a combination of essential FAs, LA and ALA. A 




that the highest variability in the FA composition of breastmilk among countries was seen in the 
ARA: DHA ratio followed by the LA: ALA ratio. The United States and Canada were the two 
countries with the lowest DHA levels (0.17%wt of total FA) and Japan had the highest levels 
(0.99%wt of total FA) (28) . 
Breastmilk naturally contains DHA and ARA and is considered the optimum nutrition for 
infants (29). The World Health Organization recommends breastfeeding infants during the first 
six months of life to promote healthy growth (5). The Food and Agriculture Organization of the 
United Nation/WHO joint commission recommend an intake of 0.3 g/day (or a minimum of 
0.2g/day) of EPA and DHA during pregnancy and lactation to ensure proper supply of these 
essential FAs to the fetus and offspring (30). 
A recent review of DHA and ARA content of breastmilk by geographic region, including 
41 countries and 4,163 samples of breastmilk, revealed that worldwide mean DHA and ARA 
levels were 0.37% (SD ±0.11%) and 0.55% (SD ±0.14%), respectively (10) . High income 
countries, including the USA, had the lowest breastmilk DHA levels compared to middle- or 
low-income countries (p<0.05) (10). 
LCPUFAs in infant formula  
Beginning in 2002, some US formula companies began adding the LCPUFAs, ARA and 
DHA, to infant formulas in an effort to mimic the average worldwide profile of human milk (1). 
For infants 0-6 months old, the FAO recommends an AI for DHA and ARA at 0.1-0.18 and 0.2-
0.3% of total energy, respectively (30). The AI increases to 10-12mg/kg weight for babies 6-24 






LCPUFAs role in fetus and infant development  
LCPUFAs play an important role in cognitive and visual development of infants (1). 
During the last trimester of pregnancy and first 18 months of life, the rate of DHA and ARA 
accretion in the brain tissue and the retina of the fetus and offspring increases rapidly (1). DHA 
is transferred through the placenta from the mother to the fetus and through breastfeeding to the 
infant. Therefore, it is important for pregnant women, both pre- and postnatally, to maintain an 
adequate level of DHA status for the development of their infants (1). 
LCPUFAs role in blood pressure 
A meta-analysis of 70 randomized controlled trials (RCTs) on n-3 LCPUFAs 
supplementation and BP, conducted with adults involving mostly hyper- and normotensive 
individuals, reported that EPA and DHA supplementation had a lowering effect on SBP (-1.52 
mm Hg; 95% CI: -2.25 to -0.79 mm Hg;) and DBP (-0.99 mm Hg; 95% CI: -1.54 to -0.44), all 
studies combined (4) . In infants, similar differences in BP were found between formula-fed and 
breast-fed babies. In the U.K., Wilson et al. (9) compared BP levels between formula-fed versus 
exclusively breastfed infants (n=301). Formula-fed infants had significantly higher mean SBP 
(94.2 mm Hg) than exclusively breastfed (90.3 mm Hg) babies. A systematic review and meta-
analysis of 15 studies, with a total number of 17,503 subjects, showed a lower SBP (95% CI, 
pooled difference of -1.4 mm Hg) in breastfed versus formula-fed babies (6) . However, another 
systematic review conducted by Owen et al. (7) showed that smaller studies (<300 subjects) 
tended to report more pooled mean differences in SBP (-2.05 mm Hg) between exclusively 
breastfed babies and exclusively formula-fed babies than larger studies (>1000 subjects)  
(-0.16mm Hg). The authors concluded that breastfeeding tends to have a small protective effect 




Some studies in full-term bottle-fed babies with LCPUFA supplemented formula 
achieved the same results as breastfed babies in lowering BP levels later in childhood (2, 12) but 
not all studies (13, 31) . Research in this area is limited and results from studies are inconclusive. 
LCPUFA intake and blood pressure in Children 
A prospective study using data from a Dutch population-based birth cohort (n=1432), 
compared two subsamples of full-term healthy children who were followed from birth and had 
medical examinations done at ages 4, 8 and 12 years (32). This study investigated the association 
between FA composition of breastmilk and BP at 12 years of age. They analyzed the RBC FA 
composition (DHA, EPA, and total n-3 LCPUFAs) of human milk consumed in a subgroup of 
breastfed babies (n =109) and compared it to a reference subgroup of infants (n= 205) who were 
never breastfed. At 12 years of age, children who consumed human milk containing higher 
amount of n-3 LCPUFA had a 4.79 mm Hg lower SBP (95% CI, -7.64 to -1.94) and a 2.47mm 
Hg lower DBP (95% CI, -4.45 to -0.49), compared to the reference group. However, n-3 
LCPUFA status was not associated with BP at 12 years of age (32). 
These findings are supported by a cross-sectional study using NHANES (2003-2005) 
data but with a different population of low birth-weight children (n=354; <10th %centile; mean 
birth-weight: 2483g) (33) . In this study, Skilton et al. (33)  investigated the hypothesis that EPA 
and DHA dietary intake in childhood lowers BP at 8 to15 years of age. As reported by these 
authors, low-birth weight was associated with increased risk of hypertension in later life (33). 
They used two 24-hour dietary recalls and categorized the EPA and DHA consumption by 
tertiles (low, medium, and high). Results showed an inverse association between the group in the 




the group in the lowest tertile. The low-birth weight group with the highest EPA and DHA intake 
had the same BP levels as normal weight children (33). 
Both studies have some limitations. To assess LCPUFA consumption, the NHANES 
cross-sectional study used two 24-hour dietary recalls. This dietary assessment method might not 
be representative of the usual or long-term dietary habits of the individual. It is also a self-
reported dietary method that relies on the subject’s memory and can under- or overestimate 
portion sizes. The Dutch study used only one sample of human milk which may or may have not 
been representative of the FA composition of human milk during the lactation period, and other 
food sources of FA intake throughout infancy were not collected (32) . As a biomarker of EPA 
and DHA intake, RBC FA composition is best used for short-term LCPUFA intake and 
considered less valid for long-term intake (32). Finally, the initial study was designed to examine 
incidence of asthma and allergy in this cohort and not BP, thus making its observations weak in 
comparison to trials that are designed with the specific aim of evaluating BP as the main 
outcome. 
Both observational studies showed an inverse association between LCPUFA intake and 
BP levels, but major differences between baseline characteristics of subjects and dietary 
assessment methodologies, make the comparison of these two studies complex. Overall, cross-
sectional designs are useful to investigate associations between n-3 PUFA and BP but they 
cannot confirm causality. On the other hand, RCTs can determine the effect of LCPUFAs on 
cardiovascular risk markers. 
Forsyth et al. (2) showed that children who were bottle-fed with LCPUFA supplemented 
formula during the first four months of life had lower mean DBP (n=65; 95% CI: -6.5 mm Hg to 




years of age compared to standard formula-fed children. However, breastfed infants and DHA 
supplemented formula-fed infants had comparable BP levels. They linked the lowering BP effect 
of human milk to its DHA content. This trial lacked data on dietary n-3 LCPUFA intake between 
the end of the trial period (four months old) and BP levels at six years of age, thus making it 
difficult to draw a cause-and-effect conclusion between these two variables. 
Similar to Forsyth et al. (2), another RCT investigated the effect of three months’ fish oil 
(FO) supplementation on BP of infants from 9 to 12 months (12). This trial was a 2x2 factorial 
design in which four groups were formed (n=83): milk or formula-fed group without FO (-FO) 
and milk and formula-fed group with FO (+FO). The results showed that at 12 months adjusted 
for age and all confounding factors, SBP was lower in the + FO group (+ FO: 100.4 mm Hg 
(±2.4) vs -FO: 106.7 mm Hg (±2.2), p-value < 0.02). In addition to dietary intake, they measured 
plasma erythrocyte (RBC) FA concentration as a biomarker of fish oil intake. RBC EPA was 
positively associated with fish intake. They found a weak inverse association between RBC 
DHA and SBP (β= -1.81, p < 0.05) and no association between RBC EPA and BP (12).   
In contrast to Forsyth et al. (2), de Jong et al. (31) did a follow-up study on children who 
were previously part of a double-blind RCT (“The Groningen LCPUFA Study”). They 
investigated the effect of LCPUFA supplementation during the first two months of life on BP at 
nine years of age. The authors concluded that short-term LCPUFA supplementation had no 
influence on BP and other markers of CVDs (31). While short-term RCTs can be valuable, long-
term RCTs allow better tracking of outcomes overtime. In that regard, Ayer et al. (13) conducted 
a longitudinal trial to examine the effect of fish oil supplementation in children, from the time of 
weaning or introduction of solids to five years of age. Children were assessed at 18 months, three 




intervention group (n= 304) received a daily supplement of 500 mL capsule of tuna oil /day with 
goal of increasing the n-3 to the n-6 ratio, and the control group (n= 304) received a daily 
supplement of a vegetable capsule with a ratio n-3: n-6 ranging from 1:15 to 1:20, representative 
of the Australian diet (13). Similar to de Jong et al. (31) findings, no differences in BP were 
found between the diet intervention and the control groups, at 8 years of age (13). 
Overall, RCTs on LCPUFA intake and BP in children have resulted in mixed findings. 
The dose and duration of LCPUFA intake, study participants’ characteristics, and methodologies 
used to assess the association between LCPUFA status and BP are different in each trial. These 
design elements make the comparison of these investigations difficult.  
LCPUFA intake and blood pressure in adolescents 
In a cross-sectional study within the prospective Raine Study, O’Sullivan et al. (34) 
investigated the relationship between dietary FA intake and BP in 14-year-old adolescents 
(n=814). They used a 3-day food record to evaluate PUFA consumption. Their results showed an 
inverse association between intake of LA, ALA, and n-3 PUFA and SBP in boys (34). Similarly, 
another cross-sectional study examined the association between LCPUFA intake and incidence 
of metabolic syndrome in a cohort of Danish children at 17 years of age (n=109) (35). They used 
a 7-day food record, pre-coded by category, and erythrocyte (RBC) FA composition from fasting 
blood samples to evaluate omega-3 FA consumption and DHA status. In contrast to the Raine 
Study, they found a positive association between RBC-DHA status and SBP (35). As noted by 
the authors, these contrasting and unexpected results could possibly be due to dietary habits or 
lifestyle factors commonly seen in teens that were not captured in their data analysis, such as 




Both studies found gender specific differences between LCPUFA intake and BP (34, 35). 
The proposed explanation was  that sex hormones may play a role in modulating either BP (34) 
or the effect of PUFA on tissue lipid composition (36). The correlation between DHA (r=0.2; 
p<0.001) and LA (r=0.1; p<0.001) dietary intake against RBC-FA status was significant in the 
Raine study (34) and a positive association was found between fish intake and RBC-DHA status 
in the Danish cohort (36). Erythrocyte FA content is a good biomarker of LCPUFA intake but it 
only indicates short-term dietary intake (32). 
Pederson et al. (37) conducted a 16-week RCT with 13-15-year-old (n=78) slightly 
overweight Danish boys to examine the effect of fish oil supplementation on CVD risk factors 
during their pubertal growth. They administered 1.5g/day supplement of n-3 LCPUFA to the 
intervention group and vegetable supplement to the control group. At the end of the intervention, 
both SBP and DBP were lower (3.8 ± 1.4 mm Hg, p < .006); 2.6 ± 1.1 mm Hg p<.01) in the FO 
group compared with the control arm. They also found a significant inverse correlation between 
changes in RBC EPA and BP when adjusted for baseline values and other confounders (37). 
Only a limited number of studies have looked at the influence of n-3 LCPUFA 
consumption in adolescence and BP levels, with conflicting results. These studies are different in 
methodology, in subject characteristics, and in duration of exposure to LCPUFA. 
Conclusion 
In light of this review, the current evidence of an association between LCPUFA 
supplementation in early life on BP in later life is inconsistent and no conclusion can be drawn in 
the healthy term pediatric population. Future RCTs should examine the effects of different doses 
of DHA supplementation on metabolic health outcomes. There is also a need for long-term RCTs 




Chapter 3: Methods 
Subject 
The aim of this study was to establish whether DHA supplementation throughout infancy 
results in lower blood pressure in children between 4 and 6 years of age who become overweight 
or obese. A detailed description of the “DHA Intake And Measurement Of Neural Development” 
(DIAMOND) study has previously been published (38). Briefly, this was a double-blinded, 
placebo controlled, randomized, parallel-group trial, investigating the maturation of infant visual 
acuity in relation to four different levels of DHA supplemented formula-fed infants at one year 
of age (38). The original cohort included 343 infants (1 to 9 days old), who were recruited and 
enrolled from two sites located in Dallas, TX and Kansas City, KS. The inclusion criteria 
included full-term, healthy, singleton-birth infants (37-42 weeks gestation), and all subjects able 
to complete the 12-months trial. All infants born with pre-existing chronic illnesses were 
excluded from the study. Consented participants were randomized into one of the four groups of 
cow’s milk-based infant formulas composed of matching nutrients except for its DHA amount: 
control (0% DHA), 0.32% DHA (17 mg/100 kcal), 0.64% DHA (34 mg/100 kcal), or 0.96% 
DHA (51 mg/100kcal) of total fatty acid. The ARA content (0.64% of total FA) of all DHA-
supplemented formulas were similar, except for the control formula that had no ARA. A subset 
of 77 infants from the Kansas City cohort had their BP and BMI measured at 6-months interval, 
from 4 to 6 years of age.  All four formulas had the same concentrations of linoleic acid (16.9-
17.5% fatty acids) and alpha-linolenic acid (1.61-1.98% fatty acids). The DHA and ARA sources 
were single-cell algal and fungal oils respectively, (Martek Biosciences in Columbia, MD). 
Subjects were randomized using a sealed envelope method that allocated subjects to one 




exclusively with the assigned formula until 4 months of age and could be introduced to other 
food sources subsequently, based on the physician’s recommendation. But parents were advised 
not to give any additional DHA supplement until the end of the 12-month trial period. 
Ethics 
The DIAMOND study protocol was approved by the Institutional Review Boards at the 
participating hospitals in Dallas, TX and Kansas City, KS as well as the University of Missouri 
Kansas City, MO. The written informed consent was presented to infant’s parents or guardians 
prior the study. 
Design and data evaluation 
This is an evaluation of secondary data obtained from children enrolled in the Kansas 
City cohort of the DIAMOND study (38). Data are measures of SBP and DBP taken at 5 
different time points. Each subject (n=77) had their SBP and DBP taken 3 times at each visit 
starting at 4 years of age, and at 6-months intervals until 6 years of age. Of the triplicate 
measures of SBP and SDP, average of 2 points was used as the average SBP and DBP. Other 
data collected were sex, DHA content of infant formulas and BMI-for-age percentiles. The 
database also included other covariates related to child’s intake and maternal characteristics that 
were disregarded for our analysis. 
Blood pressure measurements were taken at 6 months intervals from 4 to 6 years of age. 
Blood pressure was measured using “Philips SureSigns VS3”. The appropriate child and toddler 
cuff sizes were used to run BP measurements by using the index line as an indicator of size. The 
cuff was placed around the child’s arm and aligned with the brachial artery. Each BP 
measurements were performed in triplicate while the child remained seated. The method used to 




was calculated with the two last measures of BP. If CV was greater than 0.095, then two out of 
the three closest measures were selected and averaged. If all measures were equidistant, then the 
average of all 3 measures were calculated. If only two measures were taken, then these two 
measures were calculated. Finally, if only one measurement was taken, this data point was 
discarded due to lack of verifiability.  All SBP and DBP averages were further sorted by age 
group and DHA concentrations. Weight risk was assessed using the US 2000 CDC sex-specific 
BMI-for-age growth charts. Average BMI-for-age percentiles were dichotomized into two 
groups of underweight/normal weight (≤85th percentile) and overweight/obese (>85th 
percentiles).  
The Tukey Fences method was used to remove outliers from the database to compare the 
average SBP and DBP for individual DHA groups. Values below Q1-1.5 IQR or above Q3+1.5 
IQR were excluded (where Q1 = 1st or lowest quartile, IQR = Interquartile range, and Q3 = 3rd or 
highest quartile from the median). Data were then used to calculate mean SBP or DBP, BMI-for-
age percentiles, and DHA concentrations at ages 4, 4.5, 5, 5.5, and 6 years against the reference 
group. 
Statistical Analysis 
The statistical software SAS version 9.4 was used to run a GLM Procedure effect model 
to evaluate the association between BMI-for-age percentiles and DHA supplementation on SBP 
and DBP at 4, 4.5, 5.0, 5.5, and 6 years of age. All DHA-supplemented groups were combined 
into one group, then stratified by BMI-for-age (≤ 85th and > 85th percentiles), and compared to 
the control group by weight status (BMI ≤ 85th and > 85th percentiles). Outliers were included in 
the statistical analysis.  




Chapter 4: Results 
The original Kansas City cohort of the DIAMOND study enrolled 158 infants. A subset 
of 77 subjects had their blood pressure taken at 4, 4.5, 5, 5.5, and 6 years of age. Subject’s 
characteristics are provided in Table 1. The subset studied for blood pressure was 64% female 
subjects versus 53% in the original sample, but other parameters were comparable. The number 
of observations differed at each visit. The total number (n) of participants at each visit considers 
no shows and outliers and is depicted in table 2. 
Mean SBP and DBP measures at different DHA concentrations 0%, 0.32%, 0.64%, and 
0.96% of total FA) by age group (4, 4.5,5,5.5, and 6 years) dichotomized by weight status (BMI 
≤ 85%percentile for underweight/normal weight, and BMI >85% percentile for 
overweight/obese) are presented in tables 3 and 4. The average SBP and DBP (mm Hg) of the 
three DHA randomized groups and control are shown in figures 1 and 2 and Table 5 by age and 
BMI category. These tables and figures represented a preliminary look at BP and weight status 
by age. They were not used for the final statistical analysis and conclusions of my thesis. 
 Results from GLM PROC repeated measures of ANOVA are shown in Table 6 to 9 and 
Figures 3 and 4. There was a highly significant effect of BMI on SBP (p=0.0002) but no effect of 
age or group assignment (combined DHA groups vs control) (Table 6).  Mean SBP (mm Hg) for 
each age, BMI category and group are shown in Table 7.  There was no effect of group 
assignment, age or weight status on DBP (Table 8).  Mean DBP (mm Hg) for each age, BMI 










Subset study population 
(n = 77) 
 
Original study population 





Female [n (%)] 49 (64%) 84 (53%) 
 
Male [n (%)] 28 (36%) 74 (47%) 
 
Weight at birth (g) 3401.8 ± 350.4 3392.2 ± 377.2 
 





African American [n (%)] 51 (66%) 97 (62%) 
 
Caucasian [n (%)] 19 (24%) 50 (31%) 
 
Hispanic [n (%)] 5 (7%) 9 (6%) 
 
Other [n (%)]  2 (3%) 2 (1%) 
       
          
      
       
      
       
        






TABLE 2.  Number of subjects at each visit by age group, and systolic and diastolic blood 
pressure measures including missing data and outliers (total n = 77). 
 
Age groups (years) 4.0 4.5 5.0 5.5 6.0 
 
SBP1 (n) 57 63 64 63 65 
 
SBP Missing data (n) 16 10 11 11 11 
 
SBP outliers (n) 2 4 5 3 4 2 
 
 
DBP3 (n) 58 60 62 59 64 
 
DBP missing data (n) 15 9 11 13 10 
 
DBP outliers (n) 4 8 4 5 3 
 
                     
1SBP= systolic blood pressure  
2Outliers are shown here but were included in GLM PROC analysis 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 5. Relationship between DHA, BMI-for-age percentiles, and blood pressure between 4 
















Group Weight Group x 
Weight 
        
 
 
Mean SBP1 (mm Hg) (n) 
 
   
        
4 95.9 (10) 97.8 (2) 100.3 (28) 102.5 (21) NS NS NS         
4.5 99.7 (13) 96 (3) 99.0 (31) 104.7 (20) NS P=0.0509 NS         
5 100.7 (13) 106.3 (2) 97.6 (29) 104.7 (23) NS P=0.0052 NS         
5.5 102.4 (11) 111.2 (5) 78.7 (27) 73.9 (24) NS NS NS         
6 102.0 (11) 104.3 (5) 99.9 (31) 103.7 (20) NS NS NS         
 
 
Mean DBP2 (mm Hg) (n) 
 
   
        
4 65.5 (11) 59.8 (2) 61.3 (28) 60.4(21) NS NS NS         
4.5 61.1 (11) 61 (3) 60.9 (27) 64.2 (23) NS NS NS         
5 62.9 (12) 58.8 (2) 61.1 (29) 63.5 (23) NS NS NS         
5.5 62 (11) 67.6 (4) 67.0 (27) 63.6 (23) NS NS NS         
6 65.6 (11) 68 (5) 62.5(32) 65.5 (19) NS NS NS 
 
        
1SBP: systolic blood pressure (n) 







TABLE 6.  GLM PROC Model to test the nested effects of weight status, age, and group (DHA 
vs control) on systolic blood pressure (mm Hg). 
 
Source DF Sum of Squares Mean Square F Value P > F 
Model 6 1483.45752 247.24292 3.13 0.0054 
Error 324 25580.02586 78.95070   
Corrected Total 330 27063.48338    
Type I SS Age 4  97.474991 1.23 0.2960 
BMI 1  1069.531645 13.55 0.0003 
DHA 1  24.025909 0.30 0.5816 
Type  
II, III, IV SS 
Age 4  80.036217 1.01 0.4003 
BMI 1  1092.607259 13.84 0.0002 






TABLE 7. The least square estimates of systolic blood pressure 1 for each group of age, by BMI 
or DHA groups. 
 






BMI ≤ 85th percentile 100.394401 
BMI > 85th percentile 104.202532 
Control group 102.624028 
DHA group 101.972904 
 
1SBP: systolic blood pressure 




TABLE 8. GLM PROC Model to test the nested effects of weight status, age, and group (DHA 






Sum of Squares Mean Square F Value P > F 
Model 6 575.68375 95.94729 1.30 0.2581 
Error 321 23749.83378 73.98702   














BMI 1  48.0477272 0.65 0.4209 
DHA 1  50.7989088 0.69 0.4079 
 
Type  












BMI 1  66.2761624 0.90 0.3446 
















BMI ≤ 85th percentile 62.9376011 
BMI > 85th percentile 63.8791399 
Control group 63.8877661 
DHA group 62.9289749 
 
1DBP: diastolic blood pressure 




























































































































































































































































































































































Chapter 5: Discussion 
 The data did not show that DHA supplementation during infancy is associated with 
protection against higher BP in children who became overweight or obese in the ages of 4 to 6 
years compared to those who were fed the non-supplemented formula. An earlier RCT trial with 
a larger sample size, found infants fed LCPUFA- supplemented infant formula for 4 months had 
significantly lower DBP at 6 years of age compared to those who were fed a non-supplemented 
infant formula (2). Another controlled trial with teenage boys (13-15 years of age) found lower 
SBP and DBP following a 16-week dietary intervention with fish oil supplements (37), however, 
that trial is different in that the supplements containing n-3 LCPUFA were being consumed 
while the other historical trial and mine are related to possible early programming. My results are 
consistent with two previous studies that did not find any changes in BP; one study examined 
infant diet with DHA-supplemented infant formula and BP at 9 years of age (11), and the other 
looked at fish oil supplementation at time of weaning or introduction of solid and BP at 8 years 
of age (13).  
There was also no suggestion of a dose-response effect for BP among various DHA 
concentrations compared to the control group. To our knowledge, no previous studies have 
looked at this factor, so we could not compare our results. 
Timing of exposure to specific nutrients during fetal and child growth and development is 
believed to be a key factor in determining the relationship between early life exposure and later 
life health outcome. Researchers of the “Project Early Nutrition” (40) consortium assert that 
early nutrition programming effect is partly contributing to childhood obesity. In support of this 




to mother’s gestational weight gain during the first and second trimesters of pregnancy (weeks 
12-32) but not the last trimester.  
In relation to maternal DHA supplementation and BP, Hilton (42) showed that 
overweight/ obese (>85th BMI percentile) offspring of mothers who received DHA 
supplementation (600 mg/day) during pregnancy (2nd and 3rd trimesters), had lower SBP and 
DBP compared to overweight/obese children in the placebo group. In addition, these children 
had similar SBP and DBP as the underweight/normal (BMI ≤ 85th percentile) children in the 
placebo group. Therefore, improving maternal DHA status may be protective against BP in 
offspring who become overweight/obese at 5 years of age. However, our findings do not suggest 
any protection against BP when DHA supplementation is provided postnatally to term infants. 
One possible explanation for these contrasting results maybe that timing of exposure to DHA 
supplementation needs to occur at an earlier stage, prenatally rather than postnatally, to see 
desirable changes in childhood BP.   
In addition to the time of DHA supplementation, this postnatally-supplemented cohort 
differed from the cohort studies by Hilton (42) in terms of racial make-up.  Specifically, two-
thirds of the children studied here were black whereas only 30% of the children whose mothers 
received DHA during pregnancy were black. Black race trended toward higher DBP and SBP in 
the study by Hilton (42); and black children were more likely to consume more than 1.9 g 
sodium/day.  That said, mean blood pressures do not suggest major differences between the two 
populations except that children who were overweight and obese and who received DHA appear 







It was determined from this study that we can accept the null hypothesis that DHA 
supplementation has no effect on BP of young children who become overweight or obese, but 
these results should be interpreted with caution because of the small number of subjects in each 
group: we have as few as 10 and only as many as 31 children in each group with the number who 
are obese and overweight being as few as 2 in each group.  The evaluation was done primarily to 
determine if any suggestion of an effect such as observed by Hilton (42) could be found. But, the 
study did not have a power analysis and it is highly likely that it is underpowered. Additionally, 
the small number did not permit to control for the effects of factors known to contribute to 
childhood BP such as sodium intake, maternal BMI, child race, and social or lifestyle factors. 
Also, the parent study was designed to evaluate the effect of 4 doses of DHA-supplemented 
formula intake on infant’s visual acuity at one year of age. Therefore, this data may not have 
been optimal for looking at childhood BP as its primary outcome. 
 Had we had more children to evaluate, the longitudinal follow-up of the participants who 
received supplementation throughout infancy with repeated BP measurements from 4 to 6 years 
of age would have been a strength as similar studies provided much shorter duration of LCPUFA 
supplementation and did not include longitudinal follow up (2, 11, 12).  
Implications 
Unlike one previous study, I did not find any evidence that DHA-containing infant 
formulas fed during infancy influenced BP in young children who became overweight or obese 
between 4 and 6 years of age even though subjects in our study were fed the supplemented 






Intake of a LCPUFA-supplemented infant formula did not protect against higher BP 
levels seen in overweight/obese children when compared to intake of non LCPUFA-
supplemented infant formula. This contrasts with another study from our population that showed 
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